外用干扰素治疗唇疱疹和生殖器疱疹的安慰剂对照试验。

Placebo-controlled trial of topical interferon in labial and genital herpes.

作者信息

Glezerman M, Lunenfeld E, Cohen V, Sarov I, Movshovitz M, Doerner T, Shoham J, Revel M

机构信息

Division of Obstetrics and Gynecology, Soroka Medical Center, Ben Gurion University, Beer Sheva, Israel.

出版信息

Lancet. 1988 Jan 23;1(8578):150-2. doi: 10.1016/s0140-6736(88)92723-7.

DOI:10.1016/s0140-6736(88)92723-7

PMID:2892991

Abstract

The efficacy of topical interferon-beta (IFN-beta) treatment was assessed in 25 patients with herpes of the lips or genitals who completed a 2-year follow-up in a double-blind placebo-controlled trial. IFN-beta gel (10(5) U/g) 4 times daily (about 2 x 10(4) U) applied locally during eruptions (about 10 days) reduced the mean number of recurrences (p less than 0.007) and the duration of eruptions (p less than 0.007): in the placebo group these indices did not change significantly. Reduction of symptoms and severity was noted in 11 of 12 patients on IFN-beta and in only 1 on placebo. No important side-effects were recorded. Topical IFN-beta may therefore be advantageous as a time-limited local treatment of recurrent herpes simplex virus infections of the genitals and lips.

摘要

在一项双盲安慰剂对照试验中，对25例唇部或生殖器疱疹患者进行了为期2年的随访，评估了局部应用干扰素-β（IFN-β）治疗的疗效。在疱疹发作期间（约10天），每天局部应用4次IFN-β凝胶（10⁵U/g）（约2×10⁴U），可减少复发的平均次数（p<0.007）和疱疹发作的持续时间（p<0.007）：在安慰剂组中，这些指标没有显著变化。在接受IFN-β治疗的12例患者中，有11例症状和严重程度减轻，而接受安慰剂治疗的患者中只有1例减轻。未记录到重要的副作用。因此，局部应用IFN-β作为生殖器和唇部复发性单纯疱疹病毒感染的限时局部治疗可能具有优势。